JRSIS Health Care (JRSS) 10-Q 20 Sep 19 2019 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information	6 Months Ended
	Jun. 30, 2019shares
Document and Entity Information
Entity Registrant Name	JRSIS HEALTH CARE Corp
Entity Central Index Key	0001597892
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Jun. 30, 2019
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2019
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding	18,009,999
Entity File Number	000-56013
Entity Interactive Data Current	Yes
Entity Incorporation State Country Code	FL

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Current Assets:
Cash and cash equivalents	$ 553,710	$ 256,450
Accounts receivable, net	8,334,446	8,213,015
Inventories	892,758	1,163,845
Other receivables	30,835	7,590
Prepayments	1,873,647	1,826,214
Prepaid commitment fee	300,000
Amount due from related parties		149,811
Deferred expenses	291,613	291,104
Deposits for capital leases-current portion	259,843	72,700
Total current assets	12,536,852	11,980,729
Construction in progress	1,251,982	803,257
Property and equipment, net	21,548,255	37,723,969
Long term deferred expenses	1,084,521	1,238,455
Deposits for capital leases	690,107	720,306
Right-of-use assets	17,456,872
Total assets	54,568,589	52,466,716
Current Liabilities:
Accounts payable	5,364,485	3,635,761
Notes payable	300,896	668,175
Deposits received	9,782	14,213
Amount due to related parties	438,447	109,147
Other payable	21,728	49,707
Deferred tax payable-current		107,365
Tax payable		41,156
Payroll payable	615,439	383,943
Lease obligation-current portion	2,854,614	2,161,977
Convertible note	557,189
Total current liabilities	10,162,580	7,171,444
Deferred tax payable	1,748,023	1,231,462
Lease obligation	14,467,116	19,380,209
Other capital lease payable	3,750,820	2,651,084
Warrant liabilities	76,645
Total liabilities	30,205,184	30,434,199
Shareholders' equity
Common stock; $0.001 par value, 100,000,000 shares authorized; 18,009,999 and 14,975,000 issued and outstanding at June 30, 2019 and December 31, 2018, respectively	18,010	14,975
Additional Paid-in capital	15,402,240	2,191,363
Retained earnings	1,323,330	12,913,912
Other comprehensive income	(1,009,412)	(983,109)
Total shareholders' equity of the Company	15,734,168	14,137,141
Non-controlling interest	8,629,237	7,895,376
Total shareholders' equity	24,363,405	22,032,517
Total liabilities and shareholders' equity	$ 54,568,589	$ 52,466,716

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.001	$ 0.001
Common Stock, Shares Authorized	100,000,000	100,000,000
Common Stock, Shares, Issued	18,009,999	14,975,000
Common Stock, Shares, Outstanding	18,009,999	14,975,000

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Income (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Revenue:
Pharmaceuticals	$ 2,588,342	$ 2,780,456	$ 5,402,890	$ 5,488,502
Patient services	4,983,328	4,244,114	9,740,883	8,336,145
Total revenue	7,571,670	7,024,570	15,143,773	13,824,647
Operating costs and expenses:
Cost of pharmaceuticals sold	1,954,968	1,929,477	4,370,100	3,753,942
Medical consumables	995,947	959,763	1,868,539	1,740,035
Salaries and benefits	1,567,344	1,075,962	3,106,423	2,103,051
Office supplies	290,705	168,869	680,065	379,369
Vehicle expenses	76,142	35,223	158,077	66,232
Utilities expenses	101,334	82,851	297,650	261,830
Rentals and leases	28,589	26,654	56,752	53,391
Advertising and promotion expenses	1,105	15,677	26,465	15,722
Interest expense	311,493	279,292	537,353	585,296
Professional fee	63,627		104,915
Loss of fair value of convertible notes	275,189		275,189
Warrant expense	76,645		76,645
Depreciation	554,355	400,331	1,092,579	782,180
Total operating costs and expenses	6,297,443	4,974,099	12,650,752	9,741,048
Earnings from operations before other income and income taxes	1,274,227	2,050,471	2,493,021	4,083,599
Other income (expenses)	(3,753)	(4,431)	(9,368)	(8,437)
Earnings from operations before income taxes	1,270,474	2,046,040	2,483,653	4,075,162
Income tax	160,042	4,055	415,834	4,636
Net income	1,110,432	2,041,985	2,067,819	4,070,526
Less: net income attributable to non-controlling interests	455,690	612,596	744,489	1,221,158
Net income attributable to the Company	654,742	1,429,389	1,323,330	2,849,368
Comprehensive income:
Foreign currency translation adjustment attributable to non-controlling interests	(181,399)	(342,843)	(10,628)	(93,684)
Foreign currency translation adjustment attributable to the Company	(380,460)	(951,198)	(26,303)	(367,271)
Comprehensive income	548,573	747,944	2,030,888	3,609,571
Less: Comprehensive income attributable to non-controlling interests	274,291	269,753	733,861	1,127,474
Comprehensive income attributable to the Company	$ 274,282	$ 478,191	$ 1,297,027	$ 2,482,097
Basic earnings per share	$ 0.0407	$ 0.0955	$ 0.0852	$ 0.191
Diluted earnings per share	$ 0.0407	$ 0.0955	$ 0.0852	$ 0.191
Weighted average number of shares outstanding (Basic)	16,086,944	14,968,757	15,530,972	14,921,354
Weighted average number of shares outstanding (Diluted)	16,096,658	14,968,757	15,535,829	14,921,354

Consolidated Statement of Share

Consolidated Statement of Shareholders' Equity - USD ($)	Common stock	Retained Earnings	Other comprehensive income	Additional paid-in capital	Non-Controlling Interest	Total
Balance in beginning at Dec. 31, 2017	$ 14,835	$ 10,920,942	$ (93,520)	$ 2,051,503	$ 7,339,043	$ 20,232,803
Balance in beginning (in shares) at Dec. 31, 2017	14,835,000
Net income		1,419,979			608,562	2,028,541
Shares issued	$ 130			129,870		130,000
Shares issued (in shares)	130,000
Foreign currency translation adjustment			583,927		249,159	833,086
Balance in end at Mar. 31, 2018	$ 14,965	12,340,921	490,407	2,181,373	8,196,764	23,224,430
Balance in end (in shares) at Mar. 31, 2018	14,965,000
Balance in beginning at Dec. 31, 2017	$ 14,835	10,920,942	(93,520)	2,051,503	7,339,043	20,232,803
Balance in beginning (in shares) at Dec. 31, 2017	14,835,000
Net income						4,070,526
Balance in end at Jun. 30, 2018	$ 14,975	13,770,310	(460,791)	2,191,363	8,466,517	23,982,374
Balance in end (in shares) at Jun. 30, 2018	14,975,000
Balance in beginning at Mar. 31, 2018	$ 14,965	12,340,921	490,407	2,181,373	8,196,764	23,224,430
Balance in beginning (in shares) at Mar. 31, 2018	14,965,000
Net income		1,429,389			612,596	2,041,985
Shares issued	$ 10			9,990		10,000
Shares issued (in shares)	10,000
Foreign currency translation adjustment			(951,198)		(342,843)	(1,294,041)
Balance in end at Jun. 30, 2018	$ 14,975	13,770,310	(460,791)	2,191,363	8,466,517	23,982,374
Balance in end (in shares) at Jun. 30, 2018	14,975,000
Balance in beginning at Dec. 31, 2018	$ 14,975	12,913,912	(983,109)	2,191,363	7,895,376	22,032,517
Balance in beginning (in shares) at Dec. 31, 2018	14,975,000
Net income		668,588			288,799	957,387
Foreign currency translation adjustment			354,157		170,771	524,928
Balance in end at Mar. 31, 2019	$ 14,975	13,582,500	(628,952)	2,191,363	8,354,946	23,514,832
Balance in end (in shares) at Mar. 31, 2019	14,975,000
Balance in beginning at Dec. 31, 2018	$ 14,975	12,913,912	(983,109)	2,191,363	7,895,376	22,032,517
Balance in beginning (in shares) at Dec. 31, 2018	14,975,000
Net income						2,067,819
Balance in end at Jun. 30, 2019	$ 18,010	1,323,330	(1,009,412)	15,402,240	8,629,237	24,363,405
Balance in end (in shares) at Jun. 30, 2019	18,009,999
Balance in beginning at Mar. 31, 2019	$ 14,975	13,582,500	(628,952)	2,191,363	8,354,946	23,514,832
Balance in beginning (in shares) at Mar. 31, 2019	14,975,000
Net income		654,742			455,690	1,110,432
Shares issued	$ 40			299,960		300,000
Shares issued (in shares)	40,000
Foreign currency translation adjustment			(380,460)		(181,399)	(561,859)
Stock dividend	$ 2,995	(12,913,912)		12,910,917
Stock dividend (in Shares)	2,994,999
Balance in end at Jun. 30, 2019	$ 18,010	$ 1,323,330	$ (1,009,412)	$ 15,402,240	$ 8,629,237	$ 24,363,405
Balance in end (in shares) at Jun. 30, 2019	18,009,999

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Cash Flows From Operating Activities
Net income	$ 2,067,819	$ 4,070,526
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	1,092,579	782,180
Prepaid commitment expense	300,000
Loss of fair value of convertible notes	275,189
Warrant expense	76,645
Changes in operating assets and liabilities:
Accounts receivable, net	(108,366)	(2,600,389)
Inventories	276,410	(217,578)
Amount due from related parties	151,394	255,963
Prepayments and other current assets	70,149	75,110
Accounts payable	1,371,049	837,887
Amount due to related parties	349,966	65,890
Deposits received	(4,510)	1,849
Accrued expenses and other current liabilities	559,060	(496,907)
Net cash provided by operating activities	6,477,384	2,774,531
Cash Flows From Investing Activities
Purchases of property and equipment	(2,164,457)	(2,105,744)
Prepayment for property and equipment acquisition	(141,698)	(54,059)
Payment of Construction in progress	(452,709)	(655,417)
Net cash (used in) investing activities	(2,758,864)	(2,815,220)
Cash Flows From Financing Activities
Proceeds from shareholders		144,246
Payments of finance lease obligations	(6,870,433)	(1,371,672)
Interest expense	537,353	585,296
Derivative Financial Instruments	282,000
Short-term bank loan		(2,234)
Proceeds from finance lease	2,931,514
Non-cash issuance of common stock	(300,000)
Net cash (used in) financing activities	(3,419,566)	(644,364)
Effect of exchange rate fluctuation on cash and cash equivalents	(1,694)	124,555
Net increase in cash and cash equivalents	297,260	(560,498)
Cash and cash equivalents, beginning of period	256,450	884,292
Cash and cash equivalents, ending of period	553,710	323,794
Supplemental disclosure of cash flow information
Cash paid for income taxes	(415,834)	(4,636)
Cash paid for interest	$ (537,353)	$ (585,296)

Description of Business and Org

Description of Business and Organization	6 Months Ended
	Jun. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
DESCRIPTION OF BUSINESS AND ORGANIZATION	NOTE 1. DESCRIPTION OF BUSINESS AND ORGANIZATION JRSIS Health Care Corporation (the "Company" or "JRSS") was incorporated on November 20, 2013 under the laws of the State of Florida. In December 2013 JRSS acquired 100% of the equity in JRSIS Health Care Limited ("JHCL"), which is a Limited Liability Company registered in British Virgin Island ("BVI") on February 25, 2013. JHCL owns 100% of the equity in Runteng Medical Group Co., Ltd ("Runteng"), a limited liability company registered in Hong Kong on September 17, 2012. Runteng owns 70% of the equity in Harbin Jiarun Hospital Co., Ltd ("Jiarun"), a for-profit hospital incorporated in Harbin City of Heilongjiang, China in February 2006. The remaining 30% of the equity in Jiarun is owned by Junsheng Zhang, who is the Chairman of the Board of JRSIS Health Care Corporation. Jiarun is a private hospital serving patients on a municipal and county level and providing both Western and Chinese medical practices to the residents of Harbin. Jiarun also owns 100% of the equity in: ● Harbin Jiarun Hospital Co., Ltd Nanjing Road Branch ("NRB Hospital"), a hospital branch of Jiarun, incorporated in Harbin city of Heilongjiang, China in October 2017. NRB Hospital is a private hospital serving patients on a municipal and county level and providing both Western and Chinese medical practices to the residents of Harbin. ● Harbin Jiarun Hospital Co., Ltd 2 nd nd nd 30% of the equity in Jiarun is held by Junsheng Zhang and is therefore a non-controlling interest ("NCI"), accounted for pursuant to ASC 810-10-45, which states that the ownership interest in the subsidiary that is held by owners other than the parent is a non-controlling interest.

Summaries of Significant Accoun

Summaries of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
SUMMARIES OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2. SUMMARIES OF SIGNIFICANT ACCOUNTING POLICIES A. Basis of presentation The consolidated financial statements have been prepared in accordance with the United States generally accepted accounting principles ("U.S. GAAP"). B. Principles of consolidation The consolidated financial statements include the accounts of the Company and its subsidiaries. All inter-company transactions and balances have been eliminated in consolidation. Non-controlling interests represent the equity interest in Jiarun that is not attributable to the Company. Non-controlling interest is reported in the consolidated financial position within equity, separate from the Company's equity. Net income or loss and comprehensive income or loss are attributed to the Company's and the non-controlling interest. C. Use of estimates The preparation of audited consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting periods. Management makes these estimates using the best information available at the time the estimates are made; however actual results could differ from those estimates. Significant items subject to such estimates and assumptions include valuation allowances for receivables and recoverability of carrying amount and the estimated useful lives of long-lived assets. These estimates are often based on complex judgments and assumptions that management believes to be reasonable but are inherently uncertain and unpredictable. Actual results could differ from these estimates. D. Functional currency and foreign currency translation JRSS's and JHCL's functional currency is the United States dollar ("US$"). Runteng's functional currency is the Hong Kong dollar ("HK$"). The functional currency of Jiarun is the Renminbi ("RMB"). The Company's reporting currency is US$. Assets and liabilities of Runteng and Jiarun are translated at the current exchange rate at the balance sheet dates, revenues and expenses are translated at the average exchange rates during the reporting periods, and equity accounts are translated at historical rates. Translation adjustments are reported in other comprehensive income. The exchange rates used for foreign currency translation are as follows: For six months ended June 30, 2019 2018 (USD to RMB/USD to HKD) ( USD to RMB/USD to HKD Assets and liabilities period end exchange rate 6.8656 / 7.8119 6.6198 / 7.8463 Revenue and expenses period average 6.7839 / 7.8426 6.3681 / 7.8378 E. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk are cash, accounts receivable and other receivables arising from its normal business activities. The Company places its cash in what it believes to be credit-worthy financial institutions. The majority of sales are either cash receipt in advance or cash receipt upon delivery. For six months ended June 30, 2019 and 2018, no customer accounted for more than 10% of net revenue. As of June 30, 2019, and December 31, 2018, 3 and 3 customers accounted for more than 5% of net accounts receivable, respectively. For those credit sales, the Company routinely assesses the financial strength of its customers and, based upon factors surrounding the credit risk, establishes an allowance, if required, for uncollectible accounts and, as a consequence, believes that its accounts receivable credit risk exposure beyond such allowance is limited. F. Cash and cash equivalents Cash and cash equivalents include all cash, deposits in banks and other liquid investments with initial maturities of three months or less. G. Accounts receivable Accounts receivable are recorded at net realizable value consisting of the carrying amount less an allowance for uncollectible accounts as needed. The allowance for doubtful accounts is the Company's best estimate of the amount of probable credit losses in the Company's existing accounts receivable. The Company determines the allowance based on aging data, historical collection experience, customer specific facts and economic conditions. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. H. Inventories Inventories, consisting principally of pharmaceuticals, are stated at the lower of cost or market using the first-in, first-out method ("FIFO"). This policy requires the Company to make estimates regarding the market value of inventory, including an assessment of excess or obsolete inventory. The Company determines excess or obsolete inventory based on an estimate of the future demand and estimated selling prices for its products. I. Construction in progress Construction in progress represents the new hospital painting and decoration costs. All direct costs relating to the polishing and decoration are capitalized as construction in progress. No depreciation is provided in respect of construction in progress. J. Property and equipment Property and equipment is recorded at cost upon acquisition and is depreciated on a straight-line basis over the assets' estimated useful lives or over their lease terms of the assets. Expenditures for maintenance and repairs are charged to operations when incurred, while additions and betterments are capitalized. Depreciation is recorded on a straight-line basis reflective of the useful lives of the assets. When assets are retired or disposed, the asset's original cost and related accumulated depreciation are eliminated from accounts and any gain or loss is reflected in income. The estimated useful lives for property and equipment categories are as follows: Buildings and improvement 10-40 years Medical equipment 5-15 years Transportation instrument 5-10 years Office equipment 5-10 years Electronic equipment 5-10 years Software 5-10 years K. Leases In February 2016, the FASB issued ASU 2016-02–Leases (Topic 842), which increases transparency and comparability among organizations by recognizing right-of-use ("ROU") lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The ASU maintains a distinction between finance leases and operating leases, which is substantially similar to the classification criteria for distinguishing between capital leases and operating leases in the previous lease guidance. Retaining this distinction allows the recognition, measurement and presentation of expenses and cash flows arising from a lease to remain similar to the previous accounting treatment. A lessee is permitted to make an accounting policy election by class of underlying asset to exclude from balance sheet recognition any lease assets and lease liabilities with a term of 12 months or less, and instead to recognize lease expense on a straight-line basis over the lease term. For both financing and operating leases, the ROU asset and lease liability is initially measured at the present value of the lease payments in the consolidated balance sheet. In July 2018, the FASB issued ASU 2018-11 which provides entities with the option to initially apply the new lease standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption, if necessary. As discussed in Note 8, we adopted ASU 2016-02–Leases (Topic 842) effective January 1, 2019 utilizing the transition option provided by ASU 2018-11. L. Fair Value Measurement The Company applies the provisions of ASC Subtopic 820-10, Fair Value Measurements, for fair value measurements of financial assets and financial liabilities and for fair value measurements of nonfinancial items that are recognized or disclosed at fair value in the financial statements. ASC 820 also establishes a framework for measuring fair value and expands disclosures about fair value measurements. Fair value is defined as the price that would be received when selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In determining the fair value for the assets and liabilities required or permitted to be recorded, the Company considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability. ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs that may be used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2: Quoted prices in markets that are not active, or inputs that is observable, either directly or indirectly, for substantially the full term of the asset or liability; Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity). The following table sets forth by level within the fair value hierarchy our financial assets and liabilities that were accounted for at fair value on a recurring basis: Carrying Value at Fair Value Measurement at Level 1 Level 2 Level 3 Convertible Note $ 557,189 $ - $ - $ 557,189 Warrant liability $ 76,645 $ - $ - $ 76,645 A summary of changes in Warrant liability for the period ended June 30, 2019 was as follows: Balance at January 1, 2019 $ - Issuance of warrants on May 30, 2019 77,995 Change in fair value of warrant liability (1,350 ) Balance at June 30, 2019 76,645 The fair value of the outstanding warrants was calculated using the Binomial Option Pricing Model with the following assumptions at inception and on subsequent valuation date: Warrants June 30, Market price per share (USD/share) 　 $ 7.50 　 Exercise price (USD/share) 　 　 10.00 　 Risk free rate 　 　 1.737 % Dividend yield 　 　 0 % Expected term/Contractual life (years) 　 　 4.92 　 Expected volatility 　 　 50.08 % A summary of changes in Convertible Note for the period ended June 30, 2019 was as follows: Balance at January 1, 2019 $ - Issuance of Convertible Note on May 30, 2019 282,000 Fair value loss on issuance of convertible notes 288,889 Change in fair value of convertible notes (13,700 ) Balance at June 30, 2019 557,189 The fair value of the outstanding Convertible Note was calculated using the Binomial Option Pricing Model with the following assumptions at inception and on subsequent valuation date: Convertible Note June 30, Market price per share (USD/share) 　 $ 7.50 　 Exercise price (USD/share) 　 　 60% on market price 　 Risk free rate 　 　 2.02 % Dividend yield 　 　 0 % Expected term/Contractual life (years) 　 　 0.42 　 Expected volatility 　 　 48 % Cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities are reflected in the accompanying consolidated financial statements at amounts that approximate fair value because of the short-term nature of these instruments. The fair value of the Company's capital lease obligations also approximates carrying value as they bear interest at current market rates. M. Segment and geographic information The Company is operating in one segment in accordance with the accounting guidance FASB ASC topic 280, "Segment Reporting". The Company's revenues are from customers in People's Republic of China ("PRC"). All assets of the company are located in PRC. N. Revenue recognition The Company recognizes revenue when the amount of revenue can be reliably measured, it is probable that economic benefits will flow to the entity, and specific criteria have been met for each of the Company's activities as described below. Pharmaceutical sales Revenue from the sale of pharmaceuticals is recognized when it is both earned and realized. The Company's policy is to recognize the sale of pharmaceuticals when the title of the pharmaceuticals, ownership and risk of loss have transferred to the purchasers, and collection of the sales proceeds is reasonably assured, all of which generally occur when the patient receives the pharmaceuticals. Given the nature of this revenue source of the Company's business and the applicable rules guiding revenue recognition, the revenue recognition practices for the sale of pharmaceuticals do not contain estimates that materially affect results of operations nor does the Company have any policy for return of products. Patient Services In accordance with the medical licenses under which Jiarun operates, the scope of its approved medical patient service includes medical consulting, surgery, obstetrics and gynecology, pediatrics, anesthesia, clinic laboratory, medical imaging, and traditional Chinese medicine. Patient service revenue is recognized when it is both earned and realized. The Company's policy is to recognize patient service revenue when the medical service has been provided to the patient and collection of the revenue is reasonably assured. The Company provides services to both patients covered by social insurance and patients who are not covered by social insurance. The Company charges the same rates for patient services regardless of the coverage by social insurance. Patients who are not covered by social insurance are liable for the total cost of medical treatment. ● For out-patient medical services, revenue is recognized when the Company provides medical service to the patient. The Company collects payment before the patient leaves the hospital. ● For in-patient medical services, when a patient checks into the hospital, the Company estimates the approximate fee the patient will spend in the hospital based on patient's symptoms. At that time, the Company collects the estimated fees from the patient and records the payment as deposits received. During the in-patient services period, the Company recognizes revenue when the patient service is provided and deducts the cost of service from the deposit received. The Company records these transactions based on daily reports generated by the respective medical department. When medical services exceed patient deposits received the Company records revenue and accounts receivable when the patient services are provided. When a patient checks out from the hospital, the Company calculates and determines the remaining deposit, if any, and refunds the unused portion of the deposit to the patients. In the case where the patient has a balance in accounts receivable, accounts receivable are required to be paid in full at checkout. Patients covered by social insurance will receive a portion or full medical services reimbursed or paid by the social insurance agencies via prepaid cards or insurance claim settlement process. Settlement process The Company is a registered medical service vendor under the state social insurance system for various social insurance agencies. The insurance agencies include "Social Medical Insurance funded by PRC and Heilongjiang Province" and "Heilongjiang Province New Rural Cooperative Medical Care System". The Company utilizes an online system maintained by the social insurance agencies for patients who are covered by social insurance agencies. ● The Company records patients' information in the social insurance system at check in. The system determines the covered portion and amounts based on the information input to the system. ● At the time of check out, the Company collects payment for services the patients are liable for and records accounts receivable from the social insurance agencies for the portion of services covered by the social insurance. In the case that the patients have made payment during the in-patient services period, the Company refunds any amount in excess of the portion they are liable for. ● The Company is responsible for submitting supporting documents of patient services provided to the social insurance agencies for their review. The Company is also required to reconcile its records with the social insurance agencies once a month. Once the social insurance agencies approve the reconciliation, the insurance agencies will settle the accounts receivable balance in the next month following the approval. O. Income taxes The Company has adopted FASB ASC Topic 740, "Income Taxes," which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. In July 2006, the FASB issued FIN 48(ASC 740-10), Accounting for Uncertainty in Income Taxes-An Interpretation of FASB Statement No. 109 (ASC 740), which requires income tax positions to meet a more-likely-than-not recognition threshold to be recognized in the financial statements. Under FIN 48 (ASC 740-10), tax positions that previously failed to meet the more-likely-than-not threshold should be recognized in the first subsequent financial reporting period in which that threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not threshold should be derecognized in the first subsequent financial reporting period in which that threshold is no longer met. The application of tax laws and regulations is subject to legal and factual interpretation, judgment and uncertainty. Tax laws and regulations themselves are subject to change as a result of changes in fiscal policy, changes in legislation, the evolution of regulations and court rulings. Therefore, the actual liability may be materially different from our estimates, which could result in the need to record additional tax liabilities or potentially reverse previously recorded tax liabilities or deferred tax asset valuation allowance. As a result of the implementation of FIN 48 (ASC 740-10), the Company made a comprehensive review of its portfolio of tax positions in accordance with recognition standards established by FIN 48 (ASC 740-10). The Company recognized no material adjustments to liabilities or shareholder's equity as a result of the implementation. The adoption of FIN 48 did not have a material impact on the Company's unaudited consolidated financial statements. Enterprise income tax is determined under the Provisional Regulations of PRC Concerning Income Tax on Enterprises promulgated by the PRC, income tax is payable by enterprises at a rate of 25% of their taxable income. P. Earnings per share Basic earnings per common share is computed by using net income divided by the weighted average number of shares of common stock outstanding for the periods presented. Diluted earnings per share is computed by dividing net income by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding for the periods presented. Q. Reclassification The comparative figures have been reclassified to conform to current year presentation. R. Recently adopted accounting pronouncements The FASB has issued Accounting Standards Update (ASU) No. 2019-01, Leases (Topic 842): Codification Improvements. The new ASU aligns the guidance for fair value of the underlying asset by lessors that are not manufacturers or dealers in Topic 842 with that of existing guidance. As a result, the fair value of the underlying asset at lease commencement is its cost, reflecting any volume or trade discounts that may apply. However, if there has been a significant lapse of time between when the underlying asset is acquired and when the lease commences, the definition of fair value (in Topic 820, Fair Value Measurement) should be applied. The ASU also requires lessors within the scope of Topic 942, Financial Services—Depository and Lending, to present all "principal payments received under leases" within investing activities. Finally, the ASU exempts both lessees and lessors from having to provide certain interim disclosures in the fiscal year in which a company adopts the new leases standard. Leases. In February 2016, the FASB issued guidance which requires companies generally to recognize on the balance sheet operating and financing lease liabilities and corresponding right-of-use assets. This guidance is effective for fiscal years beginning after December 15, 2018 and for interim periods within those fiscal years, with early adoption permitted. The Company adopted the guidance using the modified retrospective approach as of January 1, 2019. See Note 8 - Leases for further details. We do not believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the consolidated financial position, statements of operations and cash flows.

Accounts Receivable, Net

Accounts Receivable, Net	6 Months Ended
	Jun. 30, 2019
Receivables, Net, Current [Abstract]
Accounts Receivable, Net	NOTE 3. Accounts Receivable, Net June 30 December 31 2019 2018 (Unaudited) Accounts receivable $ 8,358,843 $ 8,237,369 Less: allowance for doubtful debts 24,397 24,354 $ 8,334,446 $ 8,213,015 The Company experienced nil bad debts during six months ended June 30, 2019 and 2018.

Inventories

Inventories	6 Months Ended
	Jun. 30, 2019
Inventory Disclosure [Abstract]
Inventories	NOTE 4. Inventories At June 30, 2019 and December 31, 2018, inventories consist of the following: June 30 December 31 2019 2018 (Unaudited) Western pharmaceuticals $ 496,803 $ 809,499 Chinese herbal medicine 34,733 29,796 Medical material 357,697 321,477 Other material 3,525 3,073 $ 892,758 $ 1,163,845

Prepayment

Prepayment	6 Months Ended
	Jun. 30, 2019
Prepaid Expense, Current [Abstract]
Prepayment	NOTE 5. Prepayment At June 30, 2019 and December 31, 2018 prepayment consists of the following: June 30 December 31 2019 2018 (Unaudited) Deposits on medical equipment $ 1,407,703 $ 1,297,411 Heating fees - 135,035 Others 465,944 393,768 $ 1,873,647 $ 1,826,214

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2019
Property, Plant and Equipment [Abstract]
Property and Equipment	NOTE 6. Property and Equipment At June 30, 2019 and December 31, 2018, property and equipment, at cost, consist of: June 30, December 31, 2019 2018 (Unaudited) Transportation equipment $ 1,174,428 $ 1,000,303 Medical equipment 16,585,940 15,001,892 Electrical equipment 1,682,862 1,649,229 Office equipment and others 926,866 813,635 Buildings 24,053,766 24,011,797 Software 171,999 138,366 Total fixed assets at cost 44,595,861 42,615,222 Accumulated depreciation (5,979,379 ) (4,891,253 ) Reclass to Right-of-use assets (17,068,227 ) - Total fixed assets, net $ 21,548,255 $ 37,723,969 The Company recorded depreciation expense of $554,355 and $400,331, $1,092,579 and $782,180 for the three and six months ended June 30, 2019 and 2018, respectively.

Long term deferred expenses

Long term deferred expenses	6 Months Ended
	Jun. 30, 2019
Deferred Expenses [Abstract]
Long term deferred expenses	NOTE 7. Long term deferred expenses On May 7, 2015, July 3, 2015 and October 16, 2015, Jiarun entered into three lease agreements to lease medical equipment from Hair Finance Leasing (China) Co., Ltd. ("Hair"), a third party, for a five-year period, in which Jiarun is required to pay a consulting fee to Hair for the services provided over the five years. The consulting fee paid but attributable to the current and subsequent accounting periods was accounted for as deferred expenses and long term deferred expenses. During the year ended December 31, 2018, the Company paid approximately $1.6 million for the decoration of its outpatient building and the two Branch Hospitals. The consulting and decoration fees paid but attributable to the current and subsequent accounting periods were accounted for as deferred expenses and long term deferred expenses. The current portion of the prepaid consulting fee was recorded as deferred expenses of $291,613 and $291,104 as of June 30, 2019 and December 31, 2018. The long-term deferred expenses were $1,084,521 and $1,238,455 as of June 30, 2019 and December 31, 2018. The Company recorded consulting fee of $16,534 and $17,685 for the three months ended June 30, 2019 and 2018, and decoration fees of $40,117 and $33,144 for the three months ended June 30, 2019 and 2018, respectively. The Company recorded consulting fee of $33,254 and $35,425 for the six months ended June 30, 2019 and 2018, and decoration fees of $114,308 and $33,144 for the six months ended June 30, 2019 and 2018, respectively.

Right-of-Use Assets and Lease L

Right-of-Use Assets and Lease Liabilities	6 Months Ended
	Jun. 30, 2019
Leases [Abstract]
Right-of-Use Assets and Lease Liabilities	NOTE 8. Right-of-Use Assets and Lease Liabilities On January 1, 2019, the Company adopted Accounting Standards Codification ("ASC") Topic 842, "Leases" ("new lease standard"). The new lease standard was adopted using the optional transition method approach that allows for the cumulative effect adjustment to be recorded without restating prior periods. The Company has elected the practical expedient package related to the identification, classification and accounting for initial direct costs whereby prior conclusions do not have to be reassessed for leases that commenced before the effective date. As the Company will not reassess such conclusions, the Company has not adopted the practical expedient to use hindsight to determine the likelihood of whether a lease will be extended or terminated or whether a purchase option will be exercised. Finance lease On June 5, 2013, Jiarun entered into a lease agreement to lease its hospital building from Harbin Baiyi Real Estate Development Co., Ltd ("the Lessor"), which is owned by Junsheng Zhang, a related party. The Lease has a term of 30 years, requiring annual prepayments of a rent of RMB7,000,000. The first payment was made on September 1, 2014. At the end of the leasing period, a final payment will be made to settle the total leasing amount. Both parties agreed for Jiarun to pay RMB3,000,000 as deposit at the execution of the Leasing agreement, which will be deducted from the final rental settlement. In accordance to accounting principles and treatment, this payment was booked as deposit in our accounts. The Lessor shall return the premium for lease to Jiarun at expiration of the Contract or pledge the deposit as part of rents for the last period or periods in 2043. The implicit interest rate, which determined the rental fee after fair value was amortized, was calculated at 6.55%, which is the benchmark interest rate announced from The People's Bank of China. After the completion of all payments, the ownership of the lease item will be transferred to Jiarun. The leasing agreement for our hospital building contains the following provisions: ● Rental payments of RMB7,000,000 (equivalent to $1,144,913) per year, payable at the beginning of September. ● An option allowing the lessor to extend the lease for thirty years beyond the last renewal option exercised by the Company. ● A guarantee by the Company that the lessor will realize $nil from selling the asset at the expiration of the lease This lease is a capital lease because its term (30 years) exceeds 75% of the building's estimated economic life. In addition, the present value ($15,185,032) of the minimum lease payments exceeds 90% of the fair value of the building ($15,721,295). ● Accumulated annual amounts resulting from applying an interesting rate 6.55% to the balance of the lease obligation at the beginning of each year. The lease obligation is increased by the amount of the prior year's interest, the amount of the net rental payment at the beginning of each year; and this amount represents the guaranteed residual value at the end of the lease term. On May 7, 2015, July 3, 2015, October 16, 2015, April 6, 2016, November 25, 2016, April 5 2017 and May 25, 2019 Jiarun entered into several lease agreements to lease medical equipment and an elevator from three lease finance companies, which are all unrelated third parties, for three to five-year periods, in which Jiarun is required to make monthly or quarterly payments toward the leases. The Company was also required to pay deposits up front, which deposits will later be offset against the last quarterly payment. The medical equipment and elevator will be transferred to Jiarun upon the completion of the agreement. On March 25, 2019 Jiarun entered into a sale and leaseback agreement for the sale-leaseback of properties from Haitong Hengxin International Leasing Company Limited, with a collective net value of $2,963,067. Operating lease In August 2017 JHCC leased office space under non-cancellable operating lease agreements. Under terms of the lease agreement, from August 2017, JHCC is committed to make lease payments of approximately $36,881 per year for 5 years. This office is used for outpatient services by 2nd Branch Hospital. In December 2017 JHCC leased office space under non-cancellable operating lease agreements. Under terms of the lease agreement, from December 2017, JHCC is committed to make lease payments of approximately $68,128 per year for 5 years. This office is used by 1 st The Company's adoption of the new lease standard included new processes and controls regarding asset financing transactions, financial reporting and a system-related implementation required for the new lease standard. The Company's accounting for finance leases (formerly referred to as capital leases prior to the adoption of the new lease standard) remained substantially unchanged. The impact of the adoption of the new lease standard included the recognition of right-of-use ("ROU") assets and lease liabilities. The adoption of the new lease standard resulted in additional net lease assets and net lease liabilities of approximately $17.5 million and $17.3 million, respectively, as of June 30, 2019. As of June 30, 2019, the Company has the following amounts recorded on the Company's unaudited condensed consolidated balance sheet: June 30, Assets Operating lease assets $ 388,645 Finance lease assets 17,068,227 Total $ 17,456,872 Liabilities Current Operating lease liabilities 107,190 Finance lease liabilities 2,747,424 Long-term Operating lease liabilities 281,455 Finance lease liabilities 14,185,661 Total $ 17,321,730 The future minimum lease payments for annual capital lease obligation as of June 30, 2019 are as follows: Year Amounts 2019 $ 1,678,359 2020 2,276,516 2021 1,484,796 Thereafter 11,493,414 Total $ 16,933,085 The Company recorded finance interest lease fees of $319,073 and $312,321 for the three months ended June 30, 2019 and 2018, and recorded finance interest lease fees of $580,994 and $634,805 for the six months ended June 30, 2019 and 2018, respectively. Future annual minimum lease payments, for non-cancellable operating leases are as follows: Year ending December 31 Amount $ 2019 52,005 2020 113,076 2021 123,858 2022 99,706 388,645 The company has recorded operating lease expense of $28,589 and $26,654 for three months ended June 30, 2019 and 2018, and recorded operating lease expense of $56,752 and $53,391 for six months ended June 30, 2019 and 2018 respectively At June 30, 2019 right-of-use assets, consist of: June 30, 2019 (Unaudited) Operating lease Finance lease Total Lease assets $ 439,075 $ 17,606,451 $ 18,045,526 Accumulated amortization (50,430 ) (538,224 ) (588,654 ) Total right-of-use assets, net $ 388,645 $ 17,068,227 $ 17,456,872 The Company recorded finance lease amortization expense of $538,224 and $nil in depreciation and amortization for the six months ended June 30, 2019 and 2018, respectively. For the six months ended June 30, 2019, the amount of depreciation and amortization was $1,092,579, also included general property and equipment depreciation of $554,355. The Company recorded operating lease expense of $56,752 and $nil for the six months ended June 30, 2019 and 2018, including operating lease amortization expense of $50,430 and $nil for the six months ended June 30, 2019 and 2018, respectively.

Derivative Financial Instrument

Derivative Financial Instruments	6 Months Ended
	Jun. 30, 2019
Investments, All Other Investments [Abstract]
Derivative Financial Instruments	NOTE 9. Derivative Financial Instruments Derivative Financial Instruments The Company adopted the provisions of ASC subtopic 825-10, Financial Instruments Debt derivatives – At December 31, 2018, the Company had no debt derivatives. At June 30, 2019, the Company marked to market the fair value of the debt derivatives and determined a fair value of $557,189. The Company recorded a loss from change in fair value of debt derivatives of $275,189 for the six months ended June 30, 2019. The fair value of the embedded derivatives was determined using Binomial Option Pricing Model based on the following assumptions: (1) dividend yield of 0%, (2) expected volatility of 48%, (3) weighted average risk-free interest rate of 2.02% (4) expected life of 0.42 year, and (5) the quoted market price of the Company's common stock at each valuation date. Warrant liabilities At June 30, 2019, the Company marked to market the fair value of the warrant liability and determined a fair value of $76,645. The Company recorded a loss from change in fair value of warrant liability of $76,645 for the six months ended June 30, 2019. The fair value of the warrant liability was determined using Binomial Option Pricing Model based on the following assumptions: (1) dividend yield of 0%, (2) expected volatility of 50.08%, (3) weighted average risk-free interest rate of 1.737% (4) expected life of 4.92 years, and (5) the quoted market price of the Company's common stock at each valuation date.

Non-controlling Interests

Non-controlling Interests	6 Months Ended
	Jun. 30, 2019
Noncontrolling Interest [Abstract]
Non-controlling Interests	NOTE 10. Non-controlling Interests Jiarun is the Company's majority-owned subsidiary which is consolidated in the Company's financial statements with a non-controlling interest recognized. The Company holds a 70% equity interest in Jiarun as of June 30, 2019 and December 31, 2018. As of June 30, 2019 and December 31, 2018, NCI on the consolidated balance sheet was $8,629,237 and $7,895,376, respectively, representing the 30% of Jiarun that is owned by Junsheng Zhang. For the three months ended June 30, 2019, the comprehensive income attributable to shareholders' equity and NCI is $274,282 and $274,291 respectively. For the six months ended June 30, 2019, the comprehensive income attributable to shareholders' equity and NCI is $1,297,027 and $733,861, respectively. For the three months ended June 30, 2018, the comprehensive income attributable to shareholders' equity and NCI is $478,191 and $269,753 respectively. For the six months ended June 30, 2018, the comprehensive income attributable to shareholders' equity and NCI is $2,482,097 and $1,127,474, respectively.

Revenue

Revenue	6 Months Ended
	Jun. 30, 2019
Revenue
Revenue	NOTE 11. Revenue The Company's revenue consists of pharmaceuticals sales and patient care revenue. Three Months Ended 2019 2018 (Unaudited) (Unaudited) Pharmaceuticals: Western pharmaceuticals $ 2,028,354 $ 2,143,379 Chinese medicine 328,280 425,793 Herbal medicine 231,708 211,284 Total pharmaceuticals $ 2,588,342 $ 2,780,456 Patient services: Medical consulting $ 2,430,745 $ 2,011,281 Medical treatment 2,280,302 2,234,658 Others 272,281 (1,825 ) Total patient services $ 4,983,328 $ 4,244,114 $ 7,571,670 $ 7,024,570 Six Months Ended 2019 2018 (Unaudited) (Unaudited) Pharmaceuticals: Western pharmaceuticals $ 4,239,284 $ 4,302,818 Chinese medicine 692,990 859,010 Herbal medicine 470,616 326,674 Total pharmaceuticals $ 5,402,890 $ 5,488,502 Patient services: Medical consulting $ 4,464,609 $ 4,102,746 Medical treatment 4,862,731 4,216,113 Others 413,543 17,286 Total patient services $ 9,740,883 $ 8,336,145 $ 15,143,773 $ 13,824,647

Income Tax Expense

Income Tax Expense	6 Months Ended
	Jun. 30, 2019
Income Tax Disclosure [Abstract]
Income Tax Expense	NOTE 12. Income Tax Expense The Company uses the asset-liability method of accounting for income taxes prescribed by ASC 740 Income Taxes. The Company and its subsidiaries each file their taxes individually. United States JRSS is subject to the United States of America tax at a tax rate of 21%. No provision for the US federal income taxes has been made as the Company had no US taxable income for the periods presented, and its earnings are planned to be reinvested indefinitely into the operations of the Company in the PRC. BVI JHCL was incorporated in the BVI and, under the current laws of the BVI, it is not subject to income tax. Hong Kong Runteng was incorporated in Hong Kong and is subject to Hong Kong profits tax. Runteng is subject to Hong Kong taxation on its activities conducted in Hong Kong and income arising in or derived from Hong Kong. The applicable statutory tax rate is 16.5%. PRC Corporate Income Tax (CIT) is determined under the Provisional Regulations of PRC Concerning Income Tax on Enterprises promulgated by the PRC. Income tax is payable by enterprises at a rate of 25% of their taxable income. According to the PRC "Notice on Preferential Corporate Income Tax (CIT) Treatment for Eligible Equipment or Machinery (Cai Shui [2018] No. 54)", a 100% immediate tax deduction for CIT purposes is allowed on the condition that the unit price of each item of equipment or machinery is individually less than RMB5 million. Depreciation for tax purposes is not required. Basis differences between tax and GAAP for depreciation of property and equipment exist because in 2019 the Company purchased Eligible Equipment for RMB 12.87 million, with $415,834 deferred income tax, creating differences between tax and GAAP.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2019
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 13. Related Party Transactions The following is the list of the related parties with which the Group has had transactions: (a) Junsheng Zhang, the Chairman of the Company (b) Harbin Baiyi Real Estate Development Co., Ltd., owned by Junsheng Zhang (c) Harbin Jiarun Pharmacy Co., Ltd., owned by Junsheng Zhang (d) Heilongjiang Province Runjia Medical Equipment Company Limited, owned by Junsheng Zhang (e) Jiarun Super Market Co., Ltd., owned by Junsheng Zhang (f) Harbin Qi-run Pharmacy Limited, owned by Junsheng Zhang (g) Yanhua Xing and Weiguang Song, the former shareholders of JHCL Amount due from related parties Amount due from related parties consisted of the following as of the periods indicated: Name of related parties June 30, December 31, (Unaudited) Harbin Baiyi Real Estate Development Co., Ltd $ - $ 99,811 Junsheng Zhang - 46,500 Yanhua Xing - 2,450 Weiguang Song - 1,050 $ - $ 149,811 Amount due from Junsheng Zhang, Yanhua Xing and Weiguang Song, who are the prior shareholders of JHCL, was mainly for the paid-in capital to be paid. Amount due to related parties Amount due to related parties consisted of the following as of the periods indicated: June 30, December 31, Name of related parties 2019 2018 (Unaudited) Harbin Jiarun Pharmacy Co., Ltd $ 11,114 $ 1,211 Heilongjiang Province Runjia Medical Equipment Co., Ltd 6,773 1,614 Jiarun Super Market Co., Ltd. 39,570 39,042 Harbin Qi-run Pharmacy Co., Ltd 16,856 17,280 Junsheng Zhang 364,134 50,000 $ 438,447 $ 109,147 Amount due to Harbin Jiarun Pharmacy Co., Ltd., Harbin Qi-run pharmacy Co., Ltd and Heilongjiang Province Runjia Medical Equipment Company Limited were mainly for the balance for purchase of pharmaceuticals and medical material from these four companies. Amounts due to Junsheng Zhang represented the balance paid by Mr. Zhang for the daily operation of the Company. Related parties' transactions Purchase of pharmaceuticals and medical material from related parties consisted of the following for the periods indicated: For six months ended June 30, Name of related parties 2019 2018 Harbin Jiarun Pharmacy Co., Ltd $ 55,337 $ 125,824 Heilongjiang Province Runjia Medical Equipment Co., Ltd 7,577 6,197 Harbin Qi-run pharmacy Co., Ltd - 13,326 $ 62,914 $ 145,347 Deposits for capital leases and Capital lease obligations On June 5, 2013, Jiarun entered into a Lease Agreement to lease a new hospital building from Harbin Baiyi Real Estate Development Co., Ltd, which is owned by Junsheng Zhang, a related party. As of June 30, 2019, the Company has balance of deposits for capital leases and capital lease obligations of $436,961 and $12,170,609 respectively. As of December 31, 2018, the Company has balance of deposits for capital leases and capital lease obligations of $477,656 and $14,271,606 respectively.

Basic and Diluted Earnings Per

Basic and Diluted Earnings Per Share	6 Months Ended
	Jun. 30, 2019
Earnings Per Share [Abstract]
Basic and Diluted Earnings Per Share	NOTE 14. Basic and Diluted Earnings Per Share Basic net income per share is computed using the weighted average number of common shares outstanding during the period. Diluted net income per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common shares comprise shares issuable upon the exercise of share-based awards, using the treasury stock method. The reconciliation of the numerators and denominators of the basic and diluted earnings per share computations for income from continuing operations is shown as follows: Six Months Ended June 30, 2019 2018 (Unaudited) (Unaudited) Numerator: Net income available to common stockholders $ 1,323,330 $ 2,849,368 Denominator: Basic weighted-average number of shares outstanding 15,530,972 14,921,354 Diluted weighted-average number of shares outstanding 15,535,829 14,921,354 Net income per share: Basic $ 0.0852 $ 0.1910 Diluted 0.0852 0.1910

Contingencies and Commitment

Contingencies and Commitment	6 Months Ended
	Jun. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Contingencies and Commitment	NOTE 15. Contingencies and Commitment Certain conditions may exist as of the date the consolidated financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company's management and legal counsel assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company's legal counsel evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought. There was no contingency as of June 30, 2019 and December 31, 2018. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company's financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material would be disclosed. There was no contingency as of June 30, 2019 and December 31, 2018. Loss contingencies considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantee would be disclosed.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2019
Subsequent Events [Abstract]
Subsequent Events	NOTE 16. Subsequent Events On July 28, 2019, Jiarun's beauty center started to operate. The Management of the Company determined that there were no other reportable subsequent events to be disclosed.

Summaries of Significant Acco_2

Summaries of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Basis of presentation	A. Basis of presentation The consolidated financial statements have been prepared in accordance with the United States generally accepted accounting principles ("U.S. GAAP").
Principles of consolidation	B. Principles of consolidation The consolidated financial statements include the accounts of the Company and its subsidiaries. All inter-company transactions and balances have been eliminated in consolidation. Non-controlling interests represent the equity interest in Jiarun that is not attributable to the Company. Non-controlling interest is reported in the consolidated financial position within equity, separate from the Company's equity. Net income or loss and comprehensive income or loss are attributed to the Company's and the non-controlling interest.
Use of estimates	C. Use of estimates The preparation of audited consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting periods. Management makes these estimates using the best information available at the time the estimates are made; however actual results could differ from those estimates. Significant items subject to such estimates and assumptions include valuation allowances for receivables and recoverability of carrying amount and the estimated useful lives of long-lived assets. These estimates are often based on complex judgments and assumptions that management believes to be reasonable but are inherently uncertain and unpredictable. Actual results could differ from these estimates.
Functional currency and foreign currency translation	D. Functional currency and foreign currency translation JRSS's and JHCL's functional currency is the United States dollar ("US$"). Runteng's functional currency is the Hong Kong dollar ("HK$"). The functional currency of Jiarun is the Renminbi ("RMB"). The Company's reporting currency is US$. Assets and liabilities of Runteng and Jiarun are translated at the current exchange rate at the balance sheet dates, revenues and expenses are translated at the average exchange rates during the reporting periods, and equity accounts are translated at historical rates. Translation adjustments are reported in other comprehensive income. The exchange rates used for foreign currency translation are as follows: For six months ended June 30, 2019 2018 (USD to RMB/USD to HKD) ( USD to RMB/USD to HKD Assets and liabilities period end exchange rate 6.8656 / 7.8119 6.6198 / 7.8463 Revenue and expenses period average 6.7839 / 7.8426 6.3681 / 7.8378
Concentration of Credit Risk	E. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk are cash, accounts receivable and other receivables arising from its normal business activities. The Company places its cash in what it believes to be credit-worthy financial institutions. The majority of sales are either cash receipt in advance or cash receipt upon delivery. For six months ended June 30, 2019 and 2018, no customer accounted for more than 10% of net revenue. As of June 30, 2019, and December 31, 2018, 3 and 3 customers accounted for more than 5% of net accounts receivable, respectively. For those credit sales, the Company routinely assesses the financial strength of its customers and, based upon factors surrounding the credit risk, establishes an allowance, if required, for uncollectible accounts and, as a consequence, believes that its accounts receivable credit risk exposure beyond such allowance is limited.
Cash and cash equivalents	F. Cash and cash equivalents Cash and cash equivalents include all cash, deposits in banks and other liquid investments with initial maturities of three months or less.
Accounts receivable	G. Accounts receivable Accounts receivable are recorded at net realizable value consisting of the carrying amount less an allowance for uncollectible accounts as needed. The allowance for doubtful accounts is the Company's best estimate of the amount of probable credit losses in the Company's existing accounts receivable. The Company determines the allowance based on aging data, historical collection experience, customer specific facts and economic conditions. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.
Inventories	H. Inventories Inventories, consisting principally of pharmaceuticals, are stated at the lower of cost or market using the first-in, first-out method ("FIFO"). This policy requires the Company to make estimates regarding the market value of inventory, including an assessment of excess or obsolete inventory. The Company determines excess or obsolete inventory based on an estimate of the future demand and estimated selling prices for its products.
Construction in progress	I. Construction in progress Construction in progress represents the new hospital painting and decoration costs. All direct costs relating to the polishing and decoration are capitalized as construction in progress. No depreciation is provided in respect of construction in progress.
Property and equipment	J. Property and equipment Property and equipment is recorded at cost upon acquisition and is depreciated on a straight-line basis over the assets' estimated useful lives or over their lease terms of the assets. Expenditures for maintenance and repairs are charged to operations when incurred, while additions and betterments are capitalized. Depreciation is recorded on a straight-line basis reflective of the useful lives of the assets. When assets are retired or disposed, the asset's original cost and related accumulated depreciation are eliminated from accounts and any gain or loss is reflected in income. The estimated useful lives for property and equipment categories are as follows: Buildings and improvement 10-40 years Medical equipment 5-15 years Transportation instrument 5-10 years Office equipment 5-10 years Electronic equipment 5-10 years Software 5-10 years
Leases	K. Leases In February 2016, the FASB issued ASU 2016-02–Leases (Topic 842), which increases transparency and comparability among organizations by recognizing right-of-use ("ROU") lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The ASU maintains a distinction between finance leases and operating leases, which is substantially similar to the classification criteria for distinguishing between capital leases and operating leases in the previous lease guidance. Retaining this distinction allows the recognition, measurement and presentation of expenses and cash flows arising from a lease to remain similar to the previous accounting treatment. A lessee is permitted to make an accounting policy election by class of underlying asset to exclude from balance sheet recognition any lease assets and lease liabilities with a term of 12 months or less, and instead to recognize lease expense on a straight-line basis over the lease term. For both financing and operating leases, the ROU asset and lease liability is initially measured at the present value of the lease payments in the consolidated balance sheet. In July 2018, the FASB issued ASU 2018-11 which provides entities with the option to initially apply the new lease standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption, if necessary. As discussed in Note 8, we adopted ASU 2016-02–Leases (Topic 842) effective January 1, 2019 utilizing the transition option provided by ASU 2018-11.
Fair Value Measurement	L. Fair Value Measurement The Company applies the provisions of ASC Subtopic 820-10, Fair Value Measurements, for fair value measurements of financial assets and financial liabilities and for fair value measurements of nonfinancial items that are recognized or disclosed at fair value in the financial statements. ASC 820 also establishes a framework for measuring fair value and expands disclosures about fair value measurements. Fair value is defined as the price that would be received when selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In determining the fair value for the assets and liabilities required or permitted to be recorded, the Company considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability. ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs that may be used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2: Quoted prices in markets that are not active, or inputs that is observable, either directly or indirectly, for substantially the full term of the asset or liability; Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity). The following table sets forth by level within the fair value hierarchy our financial assets and liabilities that were accounted for at fair value on a recurring basis: Carrying Value at Fair Value Measurement at Level 1 Level 2 Level 3 Convertible Note $ 557,189 $ - $ - $ 557,189 Warrant liability $ 76,645 $ - $ - $ 76,645 A summary of changes in Warrant liability for the period ended June 30, 2019 was as follows: Balance at January 1, 2019 $ - Issuance of warrants on May 30, 2019 77,995 Change in fair value of warrant liability (1,350 ) Balance at June 30, 2019 76,645 The fair value of the outstanding warrants was calculated using the Binomial Option Pricing Model with the following assumptions at inception and on subsequent valuation date: Warrants June 30, Market price per share (USD/share) 　 $ 7.50 　 Exercise price (USD/share) 　 　 10.00 　 Risk free rate 　 　 1.737 % Dividend yield 　 　 0 % Expected term/Contractual life (years) 　 　 4.92 　 Expected volatility 　 　 50.08 % A summary of changes in Convertible Note for the period ended June 30, 2019 was as follows: Balance at January 1, 2019 $ - Issuance of Convertible Note on May 30, 2019 282,000 Fair value loss on issuance of convertible notes 288,889 Change in fair value of convertible notes (13,700 ) Balance at June 30, 2019 557,189 The fair value of the outstanding Convertible Note was calculated using the Binomial Option Pricing Model with the following assumptions at inception and on subsequent valuation date: Convertible Note June 30, Market price per share (USD/share) 　 $ 7.50 　 Exercise price (USD/share) 　 　 60% on market price 　 Risk free rate 　 　 2.02 % Dividend yield 　 　 0 % Expected term/Contractual life (years) 　 　 0.42 　 Expected volatility 　 　 48 % Cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities are reflected in the accompanying consolidated financial statements at amounts that approximate fair value because of the short-term nature of these instruments. The fair value of the Company's capital lease obligations also approximates carrying value as they bear interest at current market rates.
Segment and geographic information	M. Segment and geographic information The Company is operating in one segment in accordance with the accounting guidance FASB ASC topic 280, "Segment Reporting". The Company's revenues are from customers in People's Republic of China ("PRC"). All assets of the company are located in PRC.
Revenue recognition	N. Revenue recognition The Company recognizes revenue when the amount of revenue can be reliably measured, it is probable that economic benefits will flow to the entity, and specific criteria have been met for each of the Company's activities as described below. Pharmaceutical sales Revenue from the sale of pharmaceuticals is recognized when it is both earned and realized. The Company's policy is to recognize the sale of pharmaceuticals when the title of the pharmaceuticals, ownership and risk of loss have transferred to the purchasers, and collection of the sales proceeds is reasonably assured, all of which generally occur when the patient receives the pharmaceuticals. Given the nature of this revenue source of the Company's business and the applicable rules guiding revenue recognition, the revenue recognition practices for the sale of pharmaceuticals do not contain estimates that materially affect results of operations nor does the Company have any policy for return of products. Patient Services In accordance with the medical licenses under which Jiarun operates, the scope of its approved medical patient service includes medical consulting, surgery, obstetrics and gynecology, pediatrics, anesthesia, clinic laboratory, medical imaging, and traditional Chinese medicine. Patient service revenue is recognized when it is both earned and realized. The Company's policy is to recognize patient service revenue when the medical service has been provided to the patient and collection of the revenue is reasonably assured. The Company provides services to both patients covered by social insurance and patients who are not covered by social insurance. The Company charges the same rates for patient services regardless of the coverage by social insurance. Patients who are not covered by social insurance are liable for the total cost of medical treatment. ● For out-patient medical services, revenue is recognized when the Company provides medical service to the patient. The Company collects payment before the patient leaves the hospital. ● For in-patient medical services, when a patient checks into the hospital, the Company estimates the approximate fee the patient will spend in the hospital based on patient's symptoms. At that time, the Company collects the estimated fees from the patient and records the payment as deposits received. During the in-patient services period, the Company recognizes revenue when the patient service is provided and deducts the cost of service from the deposit received. The Company records these transactions based on daily reports generated by the respective medical department. When medical services exceed patient deposits received the Company records revenue and accounts receivable when the patient services are provided. When a patient checks out from the hospital, the Company calculates and determines the remaining deposit, if any, and refunds the unused portion of the deposit to the patients. In the case where the patient has a balance in accounts receivable, accounts receivable are required to be paid in full at checkout. Patients covered by social insurance will receive a portion or full medical services reimbursed or paid by the social insurance agencies via prepaid cards or insurance claim settlement process. Settlement process The Company is a registered medical service vendor under the state social insurance system for various social insurance agencies. The insurance agencies include "Social Medical Insurance funded by PRC and Heilongjiang Province" and "Heilongjiang Province New Rural Cooperative Medical Care System". The Company utilizes an online system maintained by the social insurance agencies for patients who are covered by social insurance agencies. ● The Company records patients' information in the social insurance system at check in. The system determines the covered portion and amounts based on the information input to the system. ● At the time of check out, the Company collects payment for services the patients are liable for and records accounts receivable from the social insurance agencies for the portion of services covered by the social insurance. In the case that the patients have made payment during the in-patient services period, the Company refunds any amount in excess of the portion they are liable for. ● The Company is responsible for submitting supporting documents of patient services provided to the social insurance agencies for their review. The Company is also required to reconcile its records with the social insurance agencies once a month. Once the social insurance agencies approve the reconciliation, the insurance agencies will settle the accounts receivable balance in the next month following the approval.
Income taxes	O. Income taxes The Company has adopted FASB ASC Topic 740, "Income Taxes," which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. In July 2006, the FASB issued FIN 48(ASC 740-10), Accounting for Uncertainty in Income Taxes-An Interpretation of FASB Statement No. 109 (ASC 740), which requires income tax positions to meet a more-likely-than-not recognition threshold to be recognized in the financial statements. Under FIN 48 (ASC 740-10), tax positions that previously failed to meet the more-likely-than-not threshold should be recognized in the first subsequent financial reporting period in which that threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not threshold should be derecognized in the first subsequent financial reporting period in which that threshold is no longer met. The application of tax laws and regulations is subject to legal and factual interpretation, judgment and uncertainty. Tax laws and regulations themselves are subject to change as a result of changes in fiscal policy, changes in legislation, the evolution of regulations and court rulings. Therefore, the actual liability may be materially different from our estimates, which could result in the need to record additional tax liabilities or potentially reverse previously recorded tax liabilities or deferred tax asset valuation allowance. As a result of the implementation of FIN 48 (ASC 740-10), the Company made a comprehensive review of its portfolio of tax positions in accordance with recognition standards established by FIN 48 (ASC 740-10). The Company recognized no material adjustments to liabilities or shareholder's equity as a result of the implementation. The adoption of FIN 48 did not have a material impact on the Company's unaudited consolidated financial statements. Enterprise income tax is determined under the Provisional Regulations of PRC Concerning Income Tax on Enterprises promulgated by the PRC, income tax is payable by enterprises at a rate of 25% of their taxable income.
Earnings per share	P. Earnings per share Basic earnings per common share is computed by using net income divided by the weighted average number of shares of common stock outstanding for the periods presented. Diluted earnings per share is computed by dividing net income by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding for the periods presented.
Reclassification	Q. Reclassification The comparative figures have been reclassified to conform to current year presentation.
Recently adopted accounting pronouncements	R. Recently adopted accounting pronouncements The FASB has issued Accounting Standards Update (ASU) No. 2019-01, Leases (Topic 842): Codification Improvements. The new ASU aligns the guidance for fair value of the underlying asset by lessors that are not manufacturers or dealers in Topic 842 with that of existing guidance. As a result, the fair value of the underlying asset at lease commencement is its cost, reflecting any volume or trade discounts that may apply. However, if there has been a significant lapse of time between when the underlying asset is acquired and when the lease commences, the definition of fair value (in Topic 820, Fair Value Measurement) should be applied. The ASU also requires lessors within the scope of Topic 942, Financial Services—Depository and Lending, to present all "principal payments received under leases" within investing activities. Finally, the ASU exempts both lessees and lessors from having to provide certain interim disclosures in the fiscal year in which a company adopts the new leases standard. Leases. In February 2016, the FASB issued guidance which requires companies generally to recognize on the balance sheet operating and financing lease liabilities and corresponding right-of-use assets. This guidance is effective for fiscal years beginning after December 15, 2018 and for interim periods within those fiscal years, with early adoption permitted. The Company adopted the guidance using the modified retrospective approach as of January 1, 2019. See Note 8 - Leases for further details. We do not believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the consolidated financial position, statements of operations and cash flows.

Summaries of Significant Acco_3

Summaries of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2019
Schedule of foreign currency translation	For six months ended June 30, 2019 2018 (USD to RMB/USD to HKD) ( USD to RMB/USD to HKD Assets and liabilities period end exchange rate 6.8656 / 7.8119 6.6198 / 7.8463 Revenue and expenses period average 6.7839 / 7.8426 6.3681 / 7.8378
Schedule of estimated useful lives for property and equipment categories	Buildings and improvement 10-40 years Medical equipment 5-15 years Transportation instrument 5-10 years Office equipment 5-10 years Electronic equipment 5-10 years Software 5-10 years
Schedule of fair value hierarchy our financial assets and liabilities	Carrying Value at Fair Value Measurement at Level 1 Level 2 Level 3 Convertible Note $ 557,189 $ - $ - $ 557,189 Warrant liability $ 76,645 $ - $ - $ 76,645
Schedule of changes in warrant liability	Balance at January 1, 2019 $ - Issuance of warrants on May 30, 2019 77,995 Change in fair value of warrant liability (1,350 ) Balance at June 30, 2019 76,645
Summary of changes in convertible note	Balance at January 1, 2019 $ - Issuance of Convertible Note on May 30, 2019 282,000 Fair value loss on issuance of convertible notes 288,889 Change in fair value of convertible notes (13,700 ) Balance at June 30, 2019 557,189
Convertible Note [Member]
Schedule of fair value of the outstanding warrants assumptions	Convertible Note June 30, Market price per share (USD/share) 　 $ 7.50 　 Exercise price (USD/share) 　 　 60% on market price 　 Risk free rate 　 　 2.02 % Dividend yield 　 　 0 % Expected term/Contractual life (years) 　 　 0.42 　 Expected volatility 　 　 48 %
Warrant liability [Member]
Schedule of fair value of the outstanding warrants assumptions	Warrants June 30, Market price per share (USD/share) 　 $ 7.50 　 Exercise price (USD/share) 　 　 10.00 　 Risk free rate 　 　 1.737 % Dividend yield 　 　 0 % Expected term/Contractual life (years) 　 　 4.92 　 Expected volatility 　 　 50.08 %

Accounts Receivable, Net (Table

Accounts Receivable, Net (Tables)	6 Months Ended
	Jun. 30, 2019
Receivables, Net, Current [Abstract]
Schedule of accounts receivable net	June 30 December 31 2019 2018 (Unaudited) Accounts receivable $ 8,358,843 $ 8,237,369 Less: allowance for doubtful debts 24,397 24,354 $ 8,334,446 $ 8,213,015

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2019
Inventory Disclosure [Abstract]
Schedule of Inventories	June 30 December 31 2019 2018 (Unaudited) Western pharmaceuticals $ 496,803 $ 809,499 Chinese herbal medicine 34,733 29,796 Medical material 357,697 321,477 Other material 3,525 3,073 $ 892,758 $ 1,163,845

Prepayment (Tables)

Prepayment (Tables)	6 Months Ended
	Jun. 30, 2019
Prepaid Expense, Current [Abstract]
Schedule of prepayment	June 30 December 31 2019 2018 (Unaudited) Deposits on medical equipment $ 1,407,703 $ 1,297,411 Heating fees - 135,035 Others 465,944 393,768 $ 1,873,647 $ 1,826,214

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2019
Property, Plant and Equipment [Abstract]
Schedule of property and equipment	June 30, December 31, 2019 2018 (Unaudited) Transportation equipment $ 1,174,428 $ 1,000,303 Medical equipment 16,585,940 15,001,892 Electrical equipment 1,682,862 1,649,229 Office equipment and others 926,866 813,635 Buildings 24,053,766 24,011,797 Software 171,999 138,366 Total fixed assets at cost 44,595,861 42,615,222 Accumulated depreciation (5,979,379 ) (4,891,253 ) Reclass to Right-of-use assets (17,068,227 ) - Total fixed assets, net $ 21,548,255 $ 37,723,969

Right-of-Use Assets and Lease_2

Right-of-Use Assets and Lease Liabilities (Tables)	6 Months Ended
	Jun. 30, 2019
Leases [Abstract]
Schedule of unaudited condensed consolidated balance sheet	June 30, Assets Operating lease assets $ 388,645 Finance lease assets 17,068,227 Total $ 17,456,872 Liabilities Current Operating lease liabilities 107,190 Finance lease liabilities 2,747,424 Long-term Operating lease liabilities 281,455 Finance lease liabilities 14,185,661 Total $ 17,321,730
Schedule of future minimum lease payments for annual capital lease obligation	Year Amounts 2019 $ 1,678,359 2020 2,276,516 2021 1,484,796 Thereafter 11,493,414 Total $ 16,933,085
Schedule of Future annual minimum lease payments, for non-cancellable operating leases	Year ending December 31 Amount $ 2019 52,005 2020 113,076 2021 123,858 2022 99,706 388,645
Schedule of right-of-use assets	June 30, 2019 (Unaudited) Operating lease Finance lease Total Lease assets $ 439,075 $ 17,606,451 $ 18,045,526 Accumulated amortization (50,430 ) (538,224 ) (588,654 ) Total right-of-use assets, net $ 388,645 $ 17,068,227 $ 17,456,872

Revenue (Tables)

Revenue (Tables)	6 Months Ended
	Jun. 30, 2019
Revenue
Schedule of revenue	Three Months Ended 2019 2018 (Unaudited) (Unaudited) Pharmaceuticals: Western pharmaceuticals $ 2,028,354 $ 2,143,379 Chinese medicine 328,280 425,793 Herbal medicine 231,708 211,284 Total pharmaceuticals $ 2,588,342 $ 2,780,456 Patient services: Medical consulting $ 2,430,745 $ 2,011,281 Medical treatment 2,280,302 2,234,658 Others 272,281 (1,825 ) Total patient services $ 4,983,328 $ 4,244,114 $ 7,571,670 $ 7,024,570 Six Months Ended 2019 2018 (Unaudited) (Unaudited) Pharmaceuticals: Western pharmaceuticals $ 4,239,284 $ 4,302,818 Chinese medicine 692,990 859,010 Herbal medicine 470,616 326,674 Total pharmaceuticals $ 5,402,890 $ 5,488,502 Patient services: Medical consulting $ 4,464,609 $ 4,102,746 Medical treatment 4,862,731 4,216,113 Others 413,543 17,286 Total patient services $ 9,740,883 $ 8,336,145 $ 15,143,773 $ 13,824,647

Related Party Transactions (Tab

Related Party Transactions (Tables)	6 Months Ended
	Jun. 30, 2019
Related Party Transactions [Abstract]
Schedule of due from related parties	Amount due from related parties consisted of the following as of the periods indicated: Name of related parties June 30, December 31, (Unaudited) Harbin Baiyi Real Estate Development Co., Ltd $ - $ 99,811 Junsheng Zhang - 46,500 Yanhua Xing - 2,450 Weiguang Song - 1,050 $ - $ 149,811
Schedule of due to related parties	Amount due to related parties consisted of the following as of the periods indicated: June 30, December 31, Name of related parties 2019 2018 (Unaudited) Harbin Jiarun Pharmacy Co., Ltd $ 11,114 $ 1,211 Heilongjiang Province Runjia Medical Equipment Co., Ltd 6,773 1,614 Jiarun Super Market Co., Ltd. 39,570 39,042 Harbin Qi-run Pharmacy Co., Ltd 16,856 17,280 Junsheng Zhang 364,134 50,000 $ 438,447 $ 109,147
Schedule of purchases from related party transactions	Purchase of pharmaceuticals and medical material from related parties consisted of the following for the periods indicated: For six months ended June 30, Name of related parties 2019 2018 Harbin Jiarun Pharmacy Co., Ltd $ 55,337 $ 125,824 Heilongjiang Province Runjia Medical Equipment Co., Ltd 7,577 6,197 Harbin Qi-run pharmacy Co., Ltd - 13,326 $ 62,914 $ 145,347

Basic and Diluted Earnings Pe_2

Basic and Diluted Earnings Per Share (Tables)	6 Months Ended
	Jun. 30, 2019
Earnings Per Share [Abstract]
Schedule of basic and diluted earnings per share	The reconciliation of the numerators and denominators of the basic and diluted earnings per share computations for income from continuing operations is shown as follows: Six Months Ended June 30, 2019 2018 (Unaudited) (Unaudited) Numerator: Net income available to common stockholders $ 1,323,330 $ 2,849,368 Denominator: Basic weighted-average number of shares outstanding 15,530,972 14,921,354 Diluted weighted-average number of shares outstanding 15,535,829 14,921,354 Net income per share: Basic $ 0.0852 $ 0.1910 Diluted 0.0852 0.1910

Description of Business and O_2

Description of Business and Organization (Details)	Jun. 30, 2013	Dec. 31, 2013	Sep. 17, 2012
Subsidiary, Runteng Medical Group Co., Ltd [Member]
Description of Business and Organization (Textual)
Noncontrolling Interest, Ownership Percentage			100.00%
JRSIS Health Care Limited [Member]
Description of Business and Organization (Textual)
Noncontrolling Interest, Ownership Percentage		100.00%
Runteng Medical Group Co., Ltd [Member]
Description of Business and Organization (Textual)
Noncontrolling Interest, Ownership Percentage	30.00%
Harbin Jiarun Hospital Co., Ltd [Member]
Description of Business and Organization (Textual)
Joint venture investment in Jiarun	70.00%

Summaries of Significant Acco_4

Summaries of Significant Accounting Policies (Details)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
HKD [Member] | Revenue And Expenses [Member]
Foreign currency translation	7.8426	7.8378
Description of foreign currency translation	period average	period average
HKD [Member] | Assets And Liabilities [Member]
Foreign currency translation	7.8119	7.8463
Description of foreign currency translation	period end exchange rate	period end exchange rate
RMB [Member] | Revenue And Expenses [Member]
Foreign currency translation	6.7839	6.3681
Description of foreign currency translation	period average	period average
RMB [Member] | Assets And Liabilities [Member]
Foreign currency translation	6.8656	6.6198
Description of foreign currency translation	period end exchange rate	period end exchange rate

Summaries of Significant Acco_5

Summaries of Significant Accounting Policies (Details 1)	6 Months Ended
	Jun. 30, 2019
Minimum [Member] | Building And Building Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Minimum [Member] | Medical Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Minimum [Member] | Transportation Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Minimum [Member] | Office Equipment And Others [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Minimum [Member] | Electronic Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Minimum [Member] | Software [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Maximum [Member] | Building And Building Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	40 years
Maximum [Member] | Medical Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	15 years
Maximum [Member] | Transportation Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Maximum [Member] | Office Equipment And Others [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Maximum [Member] | Electronic Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Maximum [Member] | Software [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years

Summaries of Significant Acco_6

Summaries of Significant Accounting Policies (Details 2) - Recurring [Member]	Jun. 30, 2019USD ($)
Warrant liability [Member]
Carrying Value	$ 76,645
Level 1 [Member] | Warrant liability [Member]
Carrying Value
Level 2 [Member] | Warrant liability [Member]
Carrying Value
Level 3 [Member] | Warrant liability [Member]
Carrying Value	76,645
Convertible Note [Member]
Carrying Value	557,189
Convertible Note [Member] | Level 1 [Member]
Carrying Value
Convertible Note [Member] | Level 2 [Member]
Carrying Value
Convertible Note [Member] | Level 3 [Member]
Carrying Value	$ 557,189

Summaries of Significant Acco_7

Summaries of Significant Accounting Policies (Details 3)	6 Months Ended
	Jun. 30, 2019USD ($)
Summaries Of Significant Accounting Policies
Balance at January 1, 2019
Issuance of warrants on May 30, 2019	77,995
Change in fair value of warrant liability	(1,350)
Balance at June 30, 2019	$ 76,645

Summaries of Significant Acco_8

Summaries of Significant Accounting Policies (Details 4)	6 Months Ended
	Jun. 30, 2019$ / shares
Convertible Note [Member]
Market price per share (USD/share)	$ 7.50
Exercise price (USD/share)	60% on market price
Risk free rate	2.02%
Dividend yield	0.00%
Expected term/Contractual life (years)	5 months 1 day
Expected volatility	48.00%
Warrant liability [Member]
Market price per share (USD/share)	$ 7.50
Exercise price (USD/share)	$ 10
Risk free rate	1.737%
Dividend yield	0.00%
Expected term/Contractual life (years)	4 years 11 months 1 day
Expected volatility	50.08%

Summaries of Significant Acco_9

Summaries of Significant Accounting Policies (Details 5)	6 Months Ended
	Jun. 30, 2019USD ($)
Summaries Of Significant Accounting Policies Details 5Abstract
Balance at January 1, 2019
Issuance of Convertible Note on May 30, 2019	282,000
Fair value loss on issuance of convertible notes	288,889
Change in fair value of convertible notes	(13,700)
Balance at June 30, 2019	$ 557,189

Summaries of Significant Acc_10

Summaries of Significant Accounting Policies (Details Textual) - Number	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Accounts Receivable [Member]
Summary of Significant Accounting Policies (Textual)
Concentration Risk, Percentage	5.00%	5.00%
Number of customers	3	3
Sales Revenue, Net [Member]
Summary of Significant Accounting Policies (Textual)
Concentration Risk, Percentage	10.00%	10.00%
People's Republic of China [Member]
Summary of Significant Accounting Policies (Textual)
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent	25.00%

Accounts Receivable, Net (Detai

Accounts Receivable, Net (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Receivables, Net, Current [Abstract]
Accounts receivable	$ 8,358,843	$ 8,237,369
Less: allowance for doubtful debts	24,397	24,354
Accounts receivable, net	$ 8,334,446	$ 8,213,015

Inventories (Details)

Inventories (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Inventory [Line Items]
Total inventories	$ 892,758	$ 1,163,845
Western Pharmaceuticals [Member]
Inventory [Line Items]
Total inventories	496,803	809,499
Chinese Herbal Medicine [Member]
Inventory [Line Items]
Total inventories	34,733	29,796
Medical Material [Member]
Inventory [Line Items]
Total inventories	357,697	321,477
Other Material [Member]
Inventory [Line Items]
Total inventories	$ 3,525	$ 3,073

Prepayment (Details)

Prepayment (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Schedule Of Prepaid Expenses Current [Line Items]
Total prepayment	$ 1,873,647	$ 1,826,214
Deposits on Medical Equipment [Member]
Schedule Of Prepaid Expenses Current [Line Items]
Total prepayment	1,407,703	1,297,411
Heating Fees [Member]
Schedule Of Prepaid Expenses Current [Line Items]
Total prepayment		135,035
Others [Member]
Schedule Of Prepaid Expenses Current [Line Items]
Total prepayment	$ 465,944	$ 393,768

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Total fixed assets at cost	$ 44,595,861	$ 42,615,222
Accumulated depreciation	(5,979,379)	(4,891,253)
Reclass to Right-of-use assets	(17,068,227)
Total fixed assets, net	21,548,255	37,723,969
Transportation Equipment [Member]
Property, Plant and Equipment [Line Items]
Total fixed assets at cost	1,174,428	1,000,303
Medical Equipment [Member]
Property, Plant and Equipment [Line Items]
Total fixed assets at cost	16,585,940	15,001,892
Electronic Equipment [Member]
Property, Plant and Equipment [Line Items]
Total fixed assets at cost	1,682,862	1,649,229
Office Equipment And Others [Member]
Property, Plant and Equipment [Line Items]
Total fixed assets at cost	926,866	813,635
Buildings [Member]
Property, Plant and Equipment [Line Items]
Total fixed assets at cost	24,053,766	24,011,797
Software [Member]
Property, Plant and Equipment [Line Items]
Total fixed assets at cost	$ 171,999	$ 138,366

Property and Equipment (Detai_2

Property and Equipment (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Property and Equipment (Textual)
Depreciation expense	$ 554,355	$ 400,331	$ 1,092,579	$ 782,180

Long term deferred expenses (De

Long term deferred expenses (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Long term deferred expenses (Textual)
Deferred expenses	$ 291,613		$ 291,613		$ 291,104
Long-term deferred expenses	1,084,521		1,084,521		1,238,455
Consulting fees	16,534	$ 17,685	33,254	$ 35,425
Decoration fees	$ 40,117	$ 33,144	$ 114,308	$ 33,144	$ 1,600,000

Right-of-Use Assets and Lease_3

Right-of-Use Assets and Lease Liabilities (Details)	Jun. 30, 2019USD ($)
Assets
Operating lease assets	$ 388,645
Finance lease assets	17,068,227
Total	17,456,872
Current
Operating lease liabilities	107,190
Finance lease liabilities	2,747,424
Long-term
Operating lease liabilities	281,455
Finance lease liabilities	14,185,661
Total	$ 17,321,730

Right-of-Use Assets and Lease_4

Right-of-Use Assets and Lease Liabilities (Details 1)	Jun. 30, 2019USD ($)
Capital leases
2019	$ 1,678,359
2020	2,276,516
2021	1,484,796
Thereafter	11,493,414
Total	$ 16,933,085

Right-of-Use Assets and Lease_5

Right-of-Use Assets and Lease Liabilities (Details 2)	Jun. 30, 2019USD ($)
Year ending December 31
2019	$ 52,005
2020	113,076
2021	123,858
2022	99,706
Total	$ 388,645

Right-of-Use Assets and Lease_6

Right-of-Use Assets and Lease Liabilities (Details 3) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Schedule Of Capital Lease Obligations and Deposit for Capital Leases [Line Items]
Lease assets	$ 18,045,526
Accumulated amortization	(588,654)
Total right-of-use assets, net	17,456,872
Operating Lease [Member]
Schedule Of Capital Lease Obligations and Deposit for Capital Leases [Line Items]
Lease assets	439,075
Accumulated amortization	(50,430)
Total right-of-use assets, net	388,645
Finance Lease [Member]
Schedule Of Capital Lease Obligations and Deposit for Capital Leases [Line Items]
Lease assets	17,606,451
Accumulated amortization	(538,224)
Total right-of-use assets, net	$ 17,068,227

Right-of-Use Assets and Lease_7

Right-of-Use Assets and Lease Liabilities (Details Textual)	1 Months Ended			3 Months Ended		6 Months Ended
	Dec. 31, 2017USD ($)	Aug. 31, 2017USD ($)	Jun. 05, 2013CNY (¥)	Jun. 30, 2019USD ($)	Jun. 30, 2018USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2018USD ($)	Mar. 25, 2019USD ($)
Right-of-Use Assets and Lease Liabilities (Textual)
Capital Lease Financing Fees				$ 319,073	$ 312,321	$ 580,994	$ 634,805
Additional net lease assets				17,500,000		17,500,000
Additional net lease liabilities				17,300,000		17,300,000
Operating lease expense				28,589	$ 26,654	56,752	53,391
Finance lease amortization expense						538,224	0
Depreciation and amortization						1,092,579
General property and equipment depreciation				$ 554,355		554,355
Operating lease expense included amortization expense						56,752	0
Operating lease amortization expense						$ 50,430	$ 0
Non-Cancellable Operating Lease Agreements [Member]
Right-of-Use Assets and Lease Liabilities (Textual)
Lease payments	$ 68,128	$ 36,881
Lease payment term	5 years	5 years
Harbin Baiyi Real Estate Development Co., Ltd [Member]
Right-of-Use Assets and Lease Liabilities (Textual)
Lease Agreement Annual Payments | ¥			¥ 7,000,000
Leasing agreement deposit | ¥			¥ 3,000,000
Term of Capital Lease			30 years
Capital Lease Obligation Interest Rate Percentage			6.55%
Description of leasing agreement						The leasing agreement for our hospital building contains the following provisions: ● Rental payments of RMB7,000,000 (equivalent to $1,144,913) per year, payable at the beginning of September. ● An option allowing the lessor to extend the lease for thirty years beyond the last renewal option exercised by the Company. ● A guarantee by the Company that the lessor will realize $nil from selling the asset at the expiration of the lease This lease is a capital lease because its term (30 years) exceeds 75% of the building's estimated economic life. In addition, the present value ($15,185,032) of the minimum lease payments exceeds 90% of the fair value of the building ($15,721,295). ● Accumulated annual amounts resulting from applying an interesting rate 6.55% to the balance of the lease obligation at the beginning of each year. The lease obligation is increased by the amount of the prior year's interest, the amount of the net rental payment at the beginning of each year; and this amount represents the guaranteed residual value at the end of the lease term.
Haitong Hengxin International Leasing Company Limited [Member] | Sale and Leaseback Agreement [Member]
Right-of-Use Assets and Lease Liabilities (Textual)
Net value of properties								$ 2,963,067

Derivative Financial Instrume_2

Derivative Financial Instruments (Details textual)	6 Months Ended
	Jun. 30, 2019USD ($)shares
Debt derivatives
Market fair value	$ 557,189
Loss from change in fair value debt derivatives	$ 275,189
Description of Embedded Derivative	The fair value of the embedded derivatives was determined using Binomial Option Pricing Model based on the following assumptions: (1) dividend yield of 0%, (2) expected volatility of 48%, (3) weighted average risk-free interest rate of 2.02% (4) expected life of 0.42 year, and (5) the quoted market price of the Company's common stock at each valuation date.
Warrant liabilities
Common stock purchase warrant | shares	28,200
Market fair value	$ 76,645
Loss from change in fair value debt derivatives	$ 76,645
Description of Embedded Derivative	The fair value of the warrant liability was determined using Binomial Option Pricing Model based on the following assumptions: (1) dividend yield of 0%, (2) expected volatility of 50.08%, (3) weighted average risk-free interest rate of 1.737% (4) expected life of 4.92 years, and (5) the quoted market price of the Company's common stock at each valuation date.

Non-controlling Interests (Deta

Non-controlling Interests (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Non-controlling Interests (Textual)
Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest	$ 274,291	$ 269,753	$ 733,861	$ 1,127,474
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	274,282	$ 478,191	1,297,027	$ 2,482,097
Stockholders' Equity Attributable to Noncontrolling Interest	$ 8,629,237		$ 8,629,237		$ 7,895,376
Jiarun [Member]
Non-controlling Interests (Textual)
Noncontrolling Interest, Ownership Percentage by Parent	70.00%		70.00%		70.00%
Jiarun [Member] | Junsheng Zhang [Member]
Non-controlling Interests (Textual)
Noncontrolling Interest, Ownership Percentage by Parent	30.00%		30.00%		30.00%

Revenue (Details)

Revenue (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Product Information [Line Items]
Revenue	$ 7,571,670	$ 7,024,570	$ 15,143,773	$ 13,824,647
Product [Member]
Product Information [Line Items]
Revenue	2,588,342	2,780,456	5,402,890	5,488,502
Product [Member] | Western Pharmaceuticals [Member]
Product Information [Line Items]
Revenue	2,028,354	2,143,379	4,239,284	4,302,818
Product [Member] | Chinese Medicine [Member]
Product Information [Line Items]
Revenue	328,280	425,793	692,990	859,010
Product [Member] | Herbal Medicine [Member]
Product Information [Line Items]
Revenue	231,708	211,284	470,616	326,674
Service [Member]
Product Information [Line Items]
Revenue	4,983,328	4,244,114	9,740,883	8,336,145
Service [Member] | Medical Consulting [Member]
Product Information [Line Items]
Revenue	2,430,745	2,011,281	4,464,609	4,102,746
Service [Member] | Medical Treatment [Member]
Product Information [Line Items]
Revenue	2,280,302	2,234,658	4,862,731	4,216,113
Service [Member] | Others [Member]
Product Information [Line Items]
Revenue	$ 272,281	$ (1,825)	$ 413,543	$ 17,286

Income Tax Expense (Details)

Income Tax Expense (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2019USD ($)	Jun. 30, 2018USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2019CNY (¥)	Jun. 30, 2018USD ($)
Income Tax Expense (Textual)
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent			25.00%	25.00%
Income Tax Expense (Benefit) | $	$ 160,042	$ 4,055	$ 415,834		$ 4,636
Tax deduction rate			100.00%	100.00%
China, Yuan Renminbi
Income Tax Expense (Textual)
Purchase of equipment				¥ 12,870,000
Deferred income tax				¥ 5,000,000
UNITED STATES
Income Tax Expense (Textual)
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent			21.00%	21.00%
HONG KONG
Income Tax Expense (Textual)
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent			16.50%	16.50%

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Related Party Transaction [Line Items]
Amount due from related parties		$ 149,811
Harbin Baiyi Real Estate Development Co., Ltd [Member]
Related Party Transaction [Line Items]
Amount due from related parties		99,811
Junsheng Zhang [Member] [Default Label]
Related Party Transaction [Line Items]
Amount due from related parties		46,500
Yanhua Xing [Member]
Related Party Transaction [Line Items]
Amount due from related parties		2,450
Weiguang Song [Member]
Related Party Transaction [Line Items]
Amount due from related parties		$ 1,050

Related Party Transactions (D_2

Related Party Transactions (Details 1) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Related Party Transaction [Line Items]
Amount due to related parties	$ 438,447	$ 109,147
Junsheng Zhang [Member] [Default Label]
Related Party Transaction [Line Items]
Amount due to related parties	364,134	50,000
Harbin Jiarun Pharmacy Co Limited [Member]
Related Party Transaction [Line Items]
Amount due to related parties	11,114	1,211
Heilongjiang Province Runjia Medical Equipment Company Limited [Member]
Related Party Transaction [Line Items]
Amount due to related parties	6,773	1,614
Jiarun Super Market Co Limited [Member]
Related Party Transaction [Line Items]
Amount due to related parties	39,570	39,042
Harbin Qirun Pharmacy Co Limited [Member]
Related Party Transaction [Line Items]
Amount due to related parties	$ 16,856	$ 17,280

Related Party Transactions (D_3

Related Party Transactions (Details 2) - USD ($)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Related Party Transaction [Line Items]
Related party transaction, purchases from related party	$ 62,914	$ 145,347
Harbin Jiarun Pharmacy Co Limited [Member]
Related Party Transaction [Line Items]
Related party transaction, purchases from related party	55,337	125,824
Heilongjiang Province Runjia Medical Equipment Company Limited [Member]
Related Party Transaction [Line Items]
Related party transaction, purchases from related party	7,577	6,197
Harbin Qirun Pharmacy Co Limited [Member]
Related Party Transaction [Line Items]
Related party transaction, purchases from related party		$ 13,326

Related Party Transactions (D_4

Related Party Transactions (Details Textual) - Harbin Baiyi Real Estate Development Co., Ltd [Member] - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Related Party Transactions (Textual)
Deposits for capital leases, ended of the period	$ 436,961	$ 477,656
Capital lease obligations, ended of the period	$ 12,170,609	$ 14,271,606

Basic and Diluted Earnings Pe_3

Basic and Diluted Earnings Per Share (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Numerator:
Net income available to common stockholders			$ 1,323,330	$ 2,849,368
Denominator:
Basic weighted-average number of shares outstanding	16,086,944	14,968,757	15,530,972	14,921,354
Diluted weighted-average number of shares outstanding	16,096,658	14,968,757	15,535,829	14,921,354
Net income per share:
Basic	$ 0.0407	$ 0.0955	$ 0.0852	$ 0.191
Diluted	$ 0.0407	$ 0.0955	$ 0.0852	$ 0.191